Age-related macular degeneration: diagnosis and management
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blind registration in Western Europe and the third leading cause of blindness worldwide. METHODS: The management of AMD is discussed with a review of current and new treatments. RESULTS: Although there is no treatment for advanced dry AMD (geographic atrophy), there have been considerable advances in the management of neovascular AMD (nAMD). Established therapies for nAMD include laser photocoagulation and photodynamic therapy (PDT), but these have largely been superseded by agents which block the action of vascular endothelial growth factor (anti-VEGF agents). Current preventative strategies involve cessation of smoking and use of specific nutritional supplements to reduce the risk of developing nAMD. CONCLUSIONS: There have been exciting advances in the treatment of nAMD and increased understanding of the genetics and pathogenic mechanisms involved will hopefully lead to the development of new therapies in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Risk factors for incident age-related macular degeneration
Tomany, S. C., Wang, J. J., van Leeuwen, R., Klein, R., Mitchell, P., Vingerling, J. R., Klein, B. E. K., Smith, W., & de Jong, P. T. V. M. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.11.010 · Cited by 621
Schmidt, S., Hauser, M. A., Scott, W. K., Postel, E. A., Agarwal, A., Gallins, P., Wong, F., Chen, Y. S., Spencer, K., Schnetz-Boutaud, N., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503822 · Cited by 335
(2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.07.023 · Cited by 279
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260
Age-related maculopathy in a multiracial United States population
Klein, R., Klein, B. E. K., Jensen, S. C., Mares-Perlman, J. A., Cruickshanks, K. J., & Palta, M. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90255-5 · Cited by 227
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD
Magnusson, K. P., Duan, S., Sigurdsson, H., Petursson, H., Yang, Z., Zhao, Y., Bernstein, P. S., Ge, J., Jonasson, F., Stefansson, E., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030005 · Cited by 226
Sepp, T., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Moore, A. T., Bird, A. C., & Yates, J. R. W. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1143 · Cited by 186
Cited by
Pennington, K. L., & DeAngelis, M. M. (2016) · Eye and Vision · doi:10.1186/s40662-016-0063-5 · Cited by 480
Loss of chromatic sensitivity in AMD and diabetes: a comparative study
O’Neill‐Biba, M., Sivaprasad, S., Rodriguez‐Carmona, M., Wolf, J. E., & Barbur, J. L. (2010) · Ophthalmic and Physiological Optics · doi:10.1111/j.1475-1313.2010.00775.x · Cited by 74
“It is generally accepted that oxidative stress, genetic variants of the CFH, ARMS 2 and/or LOC387715 genes, macular pigment optical density and smoking may well be contributory factors to this disease (Hammond et al., 1996; Beatty et al., 2000; Postel et al., 2006; Narayanan et al., 2007; Nolan et al., 2007; Cook et a…”
BackgroundCabrera, A. P., Bhaskaran, A., Xu, J., Yang, X., Scott, H. A., Mohideen, U., & Ghosh, K. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19727 · Cited by 53
Makarev, E., Cantor, C., Zhavoronkov, A., Buzdin, A., Aliper, A., & Csoka, A. B. (2014) · Aging · doi:10.18632/aging.100711 · Cited by 50
“It is the most common cause of visual impairment in the elderly (>60 years) and is broadly classified into two clinical categories, namely: the wet form (neovascular or exudative) and dry form [8].”
Background
Metadata
- Authors
- Cook, H. L., Patel, P. J., & Tufail, A.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-01
- Volume
- 85
- Issue
- 1
- Pages
- 127-149
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2116794040
- Cited by
- 131
- References
- 17
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.